George B. Abercrombie is Director at BIOCRYST PHARMACEUTICALS INC (BCRX). They have made 14 open-market trades across 2 companies since 2013, most recently 2024-06-12.
CIK 0001485939
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $22K since 2013, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BCRX | SELL | 2022-04-18 | 2022-04-20 | $11.04 | $110K | -6.3% | -11.2% | +15.4% |
| BCRX | SELL | 2022-02-15 | 2022-02-16 | $18.50 | $93K | -13.9% | -17.0% | -54.5% |
| BCRX | SELL | 2021-11-15 | 2021-11-17 | $12.27 | $61K | +0.5% | +8.6% | +56.3% |
| BCRX | SELL | 2021-09-15 | 2021-09-17 | $15.06 | $75K | -5.4% | -1.8% | -21.5% |
| BCRX | SELL | 2021-09-10 | 2021-09-14 | $15.09 | $1.1M | -3.1% | +0.3% | -24.8% |
| BCRX | SELL | 2021-07-15 | 2021-07-19 | $15.69 | $78K | +9.3% | -5.0% | -2.7% |
| BCRX | SELL | 2021-05-24 | 2021-05-26 | $13.90 | $185K | +24.8% | +25.5% | +13.2% |
| BCRX | SELL | 2021-05-10 | 2021-05-12 | $12.70 | $89K | +8.9% | +33.6% | +21.5% |
| INVA | SELL | 2018-08-21 | 2018-08-22 | $14.11 | $113K | +2.3% | +4.0% | +14.3% |
| INVA | SELL | 2018-05-21 | 2018-05-22 | $14.40 | $115K | +5.3% | +3.3% | -0.1% |
| INVA | SELL | 2018-02-21 | 2018-02-22 | $16.51 | $132K | -2.5% | +1.2% | -13.0% |
| INVA | SELL | 2017-11-21 | 2017-11-22 | $13.26 | $138K | -1.9% | +4.4% | +22.0% |
| BCRX | BUY | 2013-11-12 | 2013-11-13 | $6.19 | $19K | -26.4% | -2.7% | -2.7% |
| BCRX | BUY | 2013-03-05 | 2013-03-06 | $1.23 | $4K | -26.4% | -2.7% | -2.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.